Shares of Natus Medical Incorporated rose more than 28% on Monday after confirming a $1.2 billion acquisition by an affiliate of ArchiMed, according to a press release.
- The deal allows Natus shareholders to receive $33.50 in cash for each share in the company, a 29% premium to the closing price on April 14, 2022.
- Joshua H. Levine, Natus chairman, says the deal provides its shareholders with significant and immediate cash.
- Natus board of directors have anonymously approved the deal and recommended the shareholders adopt a merger agreement.
- Natus may still solicit proposals from third parties for 30 days continuing through May 17, 2022, and in particular cases, for a period of 35 days through May 22, 2022.
Natus reported revenue of $119.8 million in the first quarter of 2022, up 4.3% from the prior year. NTUS: NASDAQ is up +28.25%